Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 174)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 4 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
2 |
|
Bupivacaine |
Approved, Investigational |
Phase 4 |
|
2180-92-9, 38396-39-3 |
2474 |
Synonyms:
(+-)-Bupivacaine
(±)-bupivacaine
(RS)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
Abbott brand OF bupivacaine hydrochloride
ANEKAIN
Anhydrous, bupivacaine
Astra brand OF bupivacaine hydrochloride
AstraZeneca brand OF bupivacaine hydrochloride
Aventis brand OF bupivacaine hydrochloride
Bloqueina
Braun brand OF bupivacaine hydrochloride
Braun, bupivacaina
Bucaine
Bupivacain janapharm
Bupivacain RPR
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaina braun
BUPIVACAINE
Bupivacaine anhydrous
Bupivacaine carbonate
Bupivacaine HCL
Bupivacaine HCL kit
Bupivacaine hydrochloride
Bupivacaine monohydrochloride, monohydrate
Bupivacain-RPR
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
Buvacaina
|
Carbonate, bupivacaine
Carbostesin
CBupivacaine
Chirocaine
DepoBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
DL-Bupivacaine
DL-Bupivacaine|Exparel®|Marcain®|Posimir®|Sensorcaine®|W-7|Xaracoll®
Dolanaest
DUR-843
Exparel
Hydrochloride, bupivacaine
Inibsa brand OF bupivacaine hydrochloride
Janapharm, bupivacain
Jenapharm brand OF bupivacaine hydrochloride
LAC-43
LIQ865
LIQ-865
Marcain
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
Pisa brand OF bupivacaine hydrochloride
Racemic bupivacaine
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
SKY-0402
Strathmann brand OF bupivacaine hydrochloride
Svedocain sin vasoconstr
Transdur-Bupivacaine
|
|
3 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 4 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
4 |
|
Uric acid |
Investigational |
Phase 4 |
|
69-93-2 |
1175 |
Synonyms:
1H-Purine-2,6,8-triol
2,6,8-Trihydroxypurine
2,6,8-Trioxopurine
2,6,8-Trioxypurine
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Acid urate, ammonium
Acid urate, sodium
Acid, uric
Ammonium acid urate
Lithate
Lithic acid
Monohydrate, monosodium urate
Monohydrate, sodium urate
Monosodium urate
Monosodium urate monohydrate
NSC-3975
Potassium urate
|
Purine-2,6,8(1H,3H,9H)-trione
Sodium acid urate
Sodium acid urate monohydrate
Sodium urate
Sodium urate monohydrate
Trioxopurine
Urate
Urate monohydrate, monosodium
Urate monohydrate, sodium
Urate, ammonium acid
Urate, monosodium
Urate, potassium
Urate, sodium
Urate, sodium acid
URIC ACID
Uricum acidum
|
|
5 |
|
Folate |
|
Phase 4 |
|
|
|
6 |
|
Vitamin B9 |
|
Phase 4 |
|
|
|
7 |
|
Vitamin B Complex |
|
Phase 4 |
|
|
|
8 |
|
Vitamins |
|
Phase 4 |
|
|
|
9 |
|
Trace Elements |
|
Phase 4 |
|
|
|
10 |
|
Hematinics |
|
Phase 4 |
|
|
|
11 |
|
Micronutrients |
|
Phase 4 |
|
|
|
12 |
|
Anesthetics, Local |
|
Phase 4 |
|
|
|
13 |
|
Analgesics, Opioid |
|
Phase 4 |
|
|
|
14 |
|
Narcotics |
|
Phase 4 |
|
|
|
15 |
|
Tamsulosin |
Approved, Investigational |
Phase 3 |
|
106133-20-4 |
129211 |
Synonyms:
(−)-tamsulosin
(-)-Tamsulosin
(-)-YM617
(-)-YM617|Flomax®|LY-253351|Omnic®|tamsulosin hydrochloride
(R)-(−)-tamsulosin
(R)-(-)-Tamsulosin
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
(R)-5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulphonamide
5-(2-((2-(2-Ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulfonamide
5-[2-[2-(2-Ethoxyphenoxy)ethylamino]propyl]-2-methoxy-benzenesulphonamide
Flomax
Harnal
HGP-0412
HIP1402
|
HIP-1402
LY-253351
OMNIC
Pradif
Tamsolusin
Tamsulon
TAMSULOSIN
Tamsulosin hydrochloride
Tamsulosina
Tamsulosina [INN-Spanish]
Tamsulosine
Tamsulosine [INN-French]
Tamsulosinum
Tamsulosinum [INN-Latin]
YM-617
|
|
16 |
|
Mirabegron |
Approved |
Phase 3 |
|
223673-61-8 |
18319735 9865528 |
Synonyms:
BETMIGA
Betmiga®|Myrbetriq®|YM-178
MIRABEGRON
|
|
|
17 |
|
Pregabalin |
Approved, Investigational |
Phase 3 |
|
148553-50-8 |
5486971 |
Synonyms:
(R-)-3-Isobutyl gaba
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S)-PREGABALIN
(S+)-3-isobutyl gaba
3 Isobutyl gaba
3-(Aminomethyl)-5-methylhexanoic acid
3-Isobutyl gaba
ALZAIN
AXALID
CI 1008
CI-1008
|
GABA, 3-isobutyl
LECAENT
Lyrica
LYRICA CR
NERVALIN
PD 144723
PD-144723
PREGABALIN
Pregabalina
REWISCA
S-(+)-3-ISOBUTYLGABA
YNP-1807
|
|
18 |
|
Lomefloxacin |
Approved, Investigational |
Phase 3 |
|
98079-51-7 |
3948 |
Synonyms:
(+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylate
(+-)-1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
(±)-1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylate
1,4-Dihydro-6,8-difluoro-1-ethyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
Décalogiflox
LFLX
Logiflox
LOMEFLOXACIN
Lomefloxacin hydrochloride
Lomefloxacine
|
Lomefloxacino
Lomefloxacinum
Lomenfloxacin
Maxaquin
Ocacin
OKA650
Okacin
Okacyn
Pharmacia brand 1 OF lomefloxacin hydrochloride
Pharmacia brand 2 OF lomefloxacin hydrochloride
SC-47111A
UNIQUIN
|
|
19 |
|
Levofloxacin |
Approved, Investigational |
Phase 3 |
|
100986-85-4 |
149096 |
Synonyms:
(-)-Ofloxacin
(2S)-7-FLUORO-2-METHYL-6-(4-METHYLPIPERAZIN-1-YL)-10-OXO-4-OXA-1-AZATRICYCLO[7.3.1.0^{5,13}]TRIDECA-5(13),6,8,11-TETRAENE-11-CARBOXYLIC ACID
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylate
(3S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylate
(S)-(-)-9-Fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylate
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
Anhydrous, levofloxacin
Cravit
DR-3355
EVOXIL
FLOXACIN
Floxin
IQUIX
Levaquin
|
LEVOFLOXACIN
Levofloxacin anhydrous
LEVOFLOXACIN HEMIHYDRATE
Levofloxacin hydrate
Levofloxacine
Levofloxacino
Levofloxacinum
L-Ofloxacin
Ofloxacin
Ofloxacin S-(-)-form
OFLOXACIN S-(-)-FORM HEMIHYDRATE
Ofloxacin, (S)-isomer
OFTAQUIX
QUINSAIR
Quixin
RWJ-25213
TAVANIC
|
|
20 |
|
Ofloxacin |
Approved |
Phase 3 |
|
82419-36-1 |
4583 |
Synonyms:
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylate
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
Akilen
Baccidal
Bactocin
Danoflox
DL-8280
Effexin
EXOCIN
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
FLOXIN OTIC
Floxstat
Fugacin
Hoe 280
Hoe-280
Inoflox
J01MA01
Kinflocin
Kinoxacin
Liflox
Loxinter
Marfloxacin
Medofloxine
Mergexin
Novecin
Nufafloqo
Obide
Occidal
OCUFLOX
Ofcin
Oflin
Oflocee
Oflocet
|
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
O-Flox
OFLOXACIN
Ofloxacin hydrochloride
Ofloxacine
Ofloxacino
Ofloxacinum
Ofloxin
OFLX
Ofus
Onexacin
Operan
Orocin
Otonil
Pharflox
Praxin
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Sinflo
Tabrin
Taravid
Tariflox
Tarivid
TARIVID 400
TARIVID I.V.
Telbit
Tructum
Uro Tarivid
Viotisone
VISIREN
Zanocin
|
|
21 |
|
Ciprofloxacin |
Approved, Investigational |
Phase 3 |
|
85721-33-1, 93107-08-5 |
2764 |
Synonyms:
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylate
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylIC ACID
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
Anhydrous, ciprofloxacin hydrochloride
Bacquinor
BAY O 9867 FREE BASE
Baycip
BAY-O-9867 FREE BASE
BAYQ3939
BAY-Q-3939
Bernoflox
CETRAXAL
Ciflox
Cifloxin
CILOXAN
Ciprinol
Cipro
Cipro I.V.
Cipro XL
Cipro XR
CIPROBAY
|
Ciprocinol
Ciprodar
Ciprofloxacin
Ciprofloxacin dihydrochloride
Ciprofloxacin HCl
Ciprofloxacin hydrochloride
Ciprofloxacin hydrochloride anhydrous
Ciprofloxacin monohydrochloride
Ciprofloxacin monohydrochloride monohydrate
Ciprofloxacina
Ciprofloxacine
Ciprofloxacino
Ciprofloxacinum
Cipromycin
Ciproquinol
Ciproxan
Ciproxin
CPFX
CPR867
Flociprin
Floxin
Hydrochloride anhydrous, ciprofloxacin
Hydrochloride, ciprofloxacin
Monohydrate, ciprofloxacin monohydrochloride
Monohydrochloride monohydrate, ciprofloxacin
Ocuflox
OTIPRIO
Proquin XR
Septicide
VELMONIT
Velomonit
|
|
22 |
|
Propiverine |
Approved, Investigational |
Phase 3 |
|
60569-19-9 |
4942 |
Synonyms:
alpha-Diphenyl alpha-N-propoxyacetic acid-4(1-methylpiperidyl)ester
Detrunorm
DETRUNORM XL
Mictonetten
Mictonorm
|
Propiverin
Propiverina
Propiverine
PROPIVERINE HCL
PROPIVERINE hydrochloride
|
|
23 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
24 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
25 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 3 |
|
|
|
26 |
|
Adrenergic beta-Agonists |
|
Phase 3 |
|
|
|
27 |
|
Adrenergic beta-3 Receptor Agonists |
|
Phase 3 |
|
|
|
28 |
|
Adrenergic Agonists |
|
Phase 3 |
|
|
|
29 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
30 |
|
Solifenacin Succinate |
|
Phase 3 |
|
242478-38-2 |
216457 |
Synonyms:
SOLIFENACIN SUCCINATE
VESICARE
|
|
|
31 |
|
Muscarinic Antagonists |
|
Phase 3 |
|
|
|
32 |
|
Cholinergic Antagonists |
|
Phase 3 |
|
|
|
33 |
|
Cholinergic Agents |
|
Phase 3 |
|
|
|
34 |
|
Anti-Anxiety Agents |
|
Phase 3 |
|
|
|
35 |
|
calcium channel blockers |
|
Phase 3 |
|
|
|
36 |
|
Analgesics |
|
Phase 3 |
|
|
|
37 |
|
Parasympatholytics |
|
Phase 3 |
|
|
|
38 |
|
Pharmaceutical Solutions |
|
Phase 2, Phase 3 |
|
|
|
39 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 1, Phase 2 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
40 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
41 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178 38904 |
Synonyms:
Blastocarb
Carboplat
CARBOPLATIN
Carboplatine
Carboplatino
Carbosin
Carbotec
Cbdca
CIS-(1,1-CYCLOBUTANEDICARBOXYLATO)DIAMMINEPLATINUM(II)
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM
CIS-DIAMMINE(1,1-CYCLOBUTANEDICARBOXYLATO)PLATINUM(II)
|
Ercar
JM 8
JM8
JM-8
Nealorin
Neocarbo
NSC-201345
NSC-241240
PARAPLATIN
Paraplatin-AQ
Ribocarbo
|
|
42 |
|
Docetaxel |
Approved, Investigational |
Phase 1, Phase 2 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
43 |
|
Pembrolizumab |
Approved |
Phase 1, Phase 2 |
|
1374853-91-4 |
254741536 |
Synonyms:
KEYLYNK-010 COMPONENT PEMBROLIZUMAB
KEYTRUDA
Keytruda®|lambrolizumab|MK-3475
LAMBROLIZUMAB
|
MK-3475
PEMBROLIZUMAB
PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
SCH-900475
|
|
44 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
45 |
|
Neurotransmitter Agents |
|
Phase 2 |
|
|
|
46 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
47 |
|
Albumin-Bound Paclitaxel |
|
Phase 1, Phase 2 |
|
|
|
48 |
|
Antimitotic Agents |
|
Phase 1, Phase 2 |
|
|
|
49 |
|
Tubulin Modulators |
|
Phase 1, Phase 2 |
|
|
|
50 |
|
Immunoglobulins |
|
Phase 1, Phase 2 |
|
|
|
Interventional clinical trials:
(show top 50)
(show all 136)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty |
Unknown status |
NCT02444013 |
Phase 4 |
Folic acid;Placebo |
2 |
Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures |
Completed |
NCT02805504 |
Phase 4 |
Exparel;Marcaine |
3 |
A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures |
Recruiting |
NCT04826484 |
Phase 4 |
Exparel 133 miligrams per 10 milliliter injection;Bupivacaine Hydrochloride |
4 |
Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery |
Withdrawn |
NCT03591289 |
Phase 4 |
NMB with rocuronium bromide |
5 |
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome |
Completed |
NCT00239317 |
Phase 3 |
Tamusulosin |
6 |
Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome |
Completed |
NCT00239265 |
Phase 3 |
Tamuslosin |
7 |
A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms |
Completed |
NCT01908829 |
Phase 3 |
mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo |
8 |
Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot |
Completed |
NCT03927781 |
Phase 3 |
Pregabalin 300mg |
9 |
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder |
Completed |
NCT02045862 |
Phase 3 |
Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron |
10 |
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder |
Completed |
NCT01972841 |
Phase 3 |
Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron |
11 |
A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy |
Completed |
NCT01638000 |
Phase 3 |
Mirabegron;Solifenacin succinate |
12 |
A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults |
Completed |
NCT00258102 |
Phase 3 |
Levofloxacin |
13 |
A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults |
Completed |
NCT00258089 |
Phase 3 |
Levofloxacin |
14 |
Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial |
Completed |
NCT01530620 |
Phase 3 |
Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release) |
15 |
The Outcomes of Intracavernosal Umbilical Cord Mesenchymal Stem Cells Implantation in Patients With Diabetic Erectile Dysfunction |
Recruiting |
NCT04972890 |
Phase 2, Phase 3 |
|
16 |
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria |
Enrolling by invitation |
NCT04042402 |
Phase 3 |
DCR-PHXC |
17 |
A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) |
Terminated |
NCT00384891 |
Phase 3 |
Bacillus Calmette-Guérin |
18 |
A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) |
Withdrawn |
NCT02254915 |
Phase 3 |
Bacillus Calmette-Guérin |
19 |
Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients |
Completed |
NCT02307487 |
Phase 2 |
120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel |
20 |
Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells |
Completed |
NCT02291432 |
Phase 1, Phase 2 |
|
21 |
Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention |
Completed |
NCT04555343 |
Phase 1, Phase 2 |
Tranexamic acid |
22 |
A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer |
Completed |
NCT03081858 |
Phase 1, Phase 2 |
TSD-001 |
23 |
A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria |
Completed |
NCT03847909 |
Phase 2 |
DCR-PHXC;Sterile Normal Saline (0.9% NaCl) |
24 |
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis |
Completed |
NCT01613586 |
Phase 2 |
ASP3652;Placebo |
25 |
A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. |
Completed |
NCT01340027 |
Phase 2 |
Mirabegron;Solifenacin succinate;Placebo |
26 |
Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. |
Completed |
NCT03562897 |
Phase 2 |
|
27 |
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease |
Terminated |
NCT04387448 |
Phase 2 |
GFB-887;Placebo |
28 |
A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome |
Terminated |
NCT01060254 |
Phase 2 |
Placebo;JNJ-42160443 |
29 |
A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy |
Terminated |
NCT02401542 |
Phase 1, Phase 2 |
Vofatamab;Docetaxel;Placebo |
30 |
A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy |
Terminated |
NCT03123055 |
Phase 1, Phase 2 |
B-701;Pembrolizumab |
31 |
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases |
Terminated |
NCT04950114 |
Phase 2 |
GFB-887 |
32 |
A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects |
Completed |
NCT02052713 |
Phase 1 |
Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule |
33 |
A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects |
Completed |
NCT02058576 |
Phase 1 |
Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule |
34 |
Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients |
Completed |
NCT01232010 |
Phase 1 |
Mirodenafil |
35 |
Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients |
Completed |
NCT01231997 |
Phase 1 |
Udenafil |
36 |
Pilot Study of Mycophenolate Mofetil in Congenital Uropathies |
Completed |
NCT00193635 |
Phase 1 |
mycophenolate mofetil |
37 |
Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study |
Recruiting |
NCT04731376 |
Phase 1 |
Testosterone Cypionate |
38 |
Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions |
Not yet recruiting |
NCT03899298 |
Phase 1 |
|
39 |
A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral |
Not yet recruiting |
NCT03258658 |
Phase 1 |
|
40 |
Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora |
Not yet recruiting |
NCT03463239 |
Phase 1 |
|
41 |
A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma |
Terminated |
NCT02386111 |
Phase 1 |
Combination of varlilumab and sunitinib |
42 |
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer |
Terminated |
NCT02543645 |
Phase 1 |
Combination of Varlilumab and Atezolizumab |
43 |
The Effectiveness of Virtual Reality (VR) to Reduce Pain and Anxiety During Genitourinary (GU) Scans |
Unknown status |
NCT04251988 |
|
|
44 |
Effectiveness of Drainage of the Kidney by Percutaneous Nephrostomy Catheter Placement Vs. Retrograde Double J Catheter Placement in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis |
Unknown status |
NCT04594161 |
|
|
45 |
Bladder Morphology Using 2 Different Catheter Designs Foley Catheter vs. Cystosure Urinary Access System |
Unknown status |
NCT03108079 |
|
|
46 |
Pharmacology and Physiology of the Lower Urinary Tract |
Unknown status |
NCT00662064 |
|
|
47 |
Patient Empowerment for Major Surgery Preparation @ Home: Multimodal Prehabilitation in Major Elective Surgery |
Unknown status |
NCT04190719 |
|
|
48 |
The Utility of Enhanced Pre- and Post-surgical Protocols to Prevent the Spread of COVID-19 in a Large Urological Department (UroCovid Study) |
Unknown status |
NCT04409899 |
|
|
49 |
Remote Ischemic Conditioning (RIC) to Decrease Post-Operative Complications After Major Abdominal Surgery - A Phase IIa Trial |
Unknown status |
NCT03234543 |
|
|
50 |
The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones. A Randomized Clinical Trial |
Unknown status |
NCT03243682 |
|
|
|